Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37437437)

  • 21. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential.
    Pak LM; Kemeny NE; Capanu M; Chou JF; Boucher T; Cercek A; Balachandran VP; Kingham TP; Allen PJ; DeMatteo RP; Jarnagin WR; D'Angelica MI
    J Surg Oncol; 2018 Mar; 117(4):634-643. PubMed ID: 29165816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
    J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases.
    Correa-Gallego C; Gavane S; Grewal R; Cercek A; Klimstra DS; Gewirtz AN; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N; D'Angelica MI
    HPB (Oxford); 2015 Jul; 17(7):644-50. PubMed ID: 26010778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidisciplinary approach to the diagnosis and treatment of patients with potentially resectable colorectal cancer liver metastasis: results of a multicenter study.
    Han L; Xue J; Wu X; Liang G; Wu Y; Guo F; Gao S; Sun G
    Ann Palliat Med; 2022 Feb; 11(2):717-729. PubMed ID: 35249349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Conversion therapy with the intent to perform radical local treatment may not be suitable for patients with 10 or more liver metastases from colorectal cancer.
    Lin J; Sun H; Zhang W; Hong Z; Lu Z; Pan Z; Hou Z; Peng J
    Cancer Med; 2022 Nov; 11(22):4225-4235. PubMed ID: 35466587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival.
    Adam R; Delvart V; Pascal G; Valeanu A; Castaing D; Azoulay D; Giacchetti S; Paule B; Kunstlinger F; Ghémard O; Levi F; Bismuth H
    Ann Surg; 2004 Oct; 240(4):644-57; discussion 657-8. PubMed ID: 15383792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
    Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
    Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic impact of conversion hepatectomy for initially unresectable colorectal liver metastasis.
    Takamizawa Y; Inoue M; Moritani K; Tsukamoto S; Esaki M; Shimada K; Kanemitsu Y
    Langenbecks Arch Surg; 2022 Nov; 407(7):2893-2903. PubMed ID: 36068379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel score system for predicting conversion to no evidence of Disease (C-NED) in initially unresectable colorectal cancer liver metastases.
    Li W; Zhou J; Zhang T; Tai Y; Xu Y; Bai Y; Jiang Y; Lu Z; Li L; Huang J; Pan Z; Wu X; Peng J; Lin J
    Am J Cancer Res; 2022; 12(4):1648-1659. PubMed ID: 35530285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal surgical sequence for colorectal cancer liver metastases patients receiving colorectal cancer resection with simultaneous liver metastasis resection: A multicentre retrospective propensity score matching study.
    Chen Q; Zhang R; Xing B; Li C; Xiu D; Chen J; Deng Y; Chen X; Guo R; Chen F; Peng J; Sun T; Wang H; Li M; Zheng Q; Bi X; Zhao J; Zhou J; Li Z; Huang Z; Zhang Y; Zhang Y; Cai J; Zhao H
    Int J Surg; 2022 Oct; 106():106952. PubMed ID: 36220519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early evaluation of liver metastasis using spectral CT to predict outcome in patients with colorectal cancer treated with FOLFOXIRI and bevacizumab.
    Li S; Yuan L; Yue M; Xu Y; Liu S; Wang F; Liu X; Wang F; Deng J; Sun Q; Liu X; Xue C; Lu T; Zhang W; Zhou J
    Cancer Imaging; 2023 Mar; 23(1):30. PubMed ID: 36964617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.
    Ye LC; Wei Y; Zhu DX; Chen T; Xu J
    J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial.
    Liu Y; Chang W; Zhou B; Wei Y; Tang W; Liang F; Chen Y; Yan Z; Lv M; Ren L; Xu J
    Br J Surg; 2021 Apr; 108(4):373-379. PubMed ID: 33611431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total tumor volume predicts survival following liver resection in patients with hepatocellular carcinoma.
    Li MX; Zhao H; Bi XY; Li ZY; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Wei WQ; Zhao DB; Cai JQ
    Tumour Biol; 2016 Jul; 37(7):9301-10. PubMed ID: 26779628
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
    Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatic arterial infusion pump chemotherapy combined with systemic therapy for patients with advanced colorectal liver metastases: Outcomes in a newly established program.
    Walker BS; Billingsley KG; Sutton TL; Kolbeck KJ; Korngold EK; Nabavizadeh N; Dewey EN; Herzig DO; Lopez CD; Mayo SC
    J Surg Oncol; 2022 Sep; 126(3):513-522. PubMed ID: 35522249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
    Cheng SH; Cheng YJ; Jin ZY; Xue HD
    Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic factors of patients with unresectable liver metastasis from colorectal cancer after failed conversion chemotherapy].
    He H; Shen W; Chen W; Liu H; Gong W; Fu J; Hu X; Cui L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1261-1267. PubMed ID: 30506537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution.
    Ammori JB; Kemeny NE; Fong Y; Cercek A; Dematteo RP; Allen PJ; Kingham TP; Gonen M; Paty PB; Jarnagin WR; D'Angelica MI
    Ann Surg Oncol; 2013 Sep; 20(9):2901-7. PubMed ID: 23771246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.